The move could mean savings for consumers. Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly with drug manufacturers ...

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.

Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...

Ozempic and Wegovy have been added to Medicare's list of drugs, whose prices will be negotiated between drug makers and the government.

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug ...

However, the Centers for Medicare and Medicaid Services (CMS) could soon throw a monkey wrench into Novo Nordisk's momentum. The agency announced last week that Ozempic and Wegovy, along with Novo ...

The agency announced last week that Ozempic and Wegovy, along with Novo's other semaglutide GLP-1 diabetes drug Rybelsus, are at the top of its list for 2027 Medicare drug price negotiations.

Dosage strengths, formulations and packaging prices for Ozempic, Rybelsus and Wegovy would be adjusted to meet that monthly price. Semaglutide products in Medicare are also already likely to be ...

Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly ...

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...